News

An artificial intelligence (AI)-powered analysis of more than 11,000 posts on social media or in online community groups found that myasthenia gravis (MG) patients use these platforms primarily to discuss the negative impact of their disease symptoms and their feelings about MG treatments. Most of the posts…

HNSA-5487, an investigational therapy being developed for potential use in myasthenia gravis (MG) and other autoimmune diseases, was safe and rapidly lowered the levels of immunoglobulin G (IgG) antibodies in the bloodstream, according to data from a Phase 1 clinical trial. IgGs are a class of antibodies found in…

A Phase 1 clinical trial for IGM-2644, a potential first-in-class immune T-cell engager therapy for generalized myasthenia gravis (gMG), should begin by the end of the year, said its developer IGM Biosciences. “Our early pivot to using T-cell engagers in autoimmune disease has enabled significant progress on these…

The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following chemoimmunotherapy for gastric cancer that included sintilimab showcases the need to better understand how this treatment can induce the immune disorder, said researchers in China. Sintilimab is a type of…

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the skin, or subcutaneously, appears to be as effective as the intravenous treatment Vyvgart (efgartigimod alfa) at reducing IgG antibodies, including those that cause the disease. That’s according to data…

Amgen’s antibody-based therapy inebilizumab reduces the severity of generalized myasthenia gravis (MG), according to top-line data from a Phase 3 clinical trial. Dubbed MINT (NCT04524273), the study showed inebilizumab’s therapeutic efficacy in gMG patients who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) or muscle-specific…

ARGX-119, an antibody designed to increase the activity of the muscle-specific kinase (MuSK) protein, protected against the development of neuromuscular disease in mice in a model of MuSK-associated myasthenia gravis (MG), and eased or reversed evident symptoms in animals with disease onset, scientists report. With further work, such an…

Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated…

Treatment with the immunosuppressant Prograf (tacrolimus) within one year of the onset of juvenile myasthenia gravis (JMG) was found to be safe and effective in a study of pediatric patients in China. Patients who were started on Prograf earlier after JMG onset were significantly more likely to achieve…

The use of myasthenia gravis (MG) treatments did not increase COVID-19 infection risk or severity, according to a new study of Chinese patients with both generalized myasthenia gravis (gMG) and ocular types of MG. In fact, continuing treatment with nonspecific nonsteroidal immunosuppressants and antibody therapies during infection…